KRAS and pancreatic ductal adenocarcinoma: However, functional SMAD4 inactivation alone is not sufficient for tumour initiation, but it is thought to promote tumour progression in conjunction with additional alterations, e.g. activating KRAS (pancreatic duct adenocarcinoma) or inactivating APC alterations (colorectal cancer) [34].